Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT04281420 is registered in ClinicalTrials.gov with Antengene Therapeutics Limited as lead sponsor.

NCT NCT04281420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04281420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label Study of the Safety and Tolerability of ATG-019, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Lead sponsor
Antengene Therapeutics Limited
Phase
Phase 1
Overall status
Terminated
Start date
April 13, 2020
Completion date
October 2, 2023
Enrollment
20 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, non-hodgkin's lymphoma